Literature DB >> 28412063

Diagnostic Performance of Magnetic Resonance Imaging for the Detection of Bone Metastasis in Prostate Cancer: A Systematic Review and Meta-analysis.

Sungmin Woo1, Chong Hyun Suh2, Sang Youn Kim3, Jeong Yeon Cho4, Seung Hyup Kim4.   

Abstract

CONTEXT: Magnetic resonance imaging (MRI) has been tested for detecting bone metastasis and has shown promising results. Yet, consensus has not been reached regarding whether it can replace the role of bone scintigraphy in this clinical setting or not.
OBJECTIVE: To review the diagnostic performance of contemporary (≥1.5 T) MRI for the detection of bone metastasis in patients with prostate cancer. EVIDENCE ACQUISITION: MEDLINE and EMBASE were searched up to January 22, 2017. We included studies that used MRI using ≥1.5-T scanners for the detection of bone metastasis in patients with prostate cancer, using histopathology or best value comparator as the reference standard. Two independent reviewers assessed the methodological quality using the Quality Assessment of Diagnostic Accuracy Studies-2 tool. Per-patient sensitivity and specificity of included studies were calculated, and pooled and plotted in a hierarchical summary receiver operating characteristic plot. Meta-regression and sensitivity analyses were performed. EVIDENCE SYNTHESIS: Ten studies (1031 patients) were included. Pooled sensitivity was 0.96 (95% confidence interval [CI] 0.87-0.99) with a specificity of 0.98 (95% CI 0.93-0.99). At meta-regression analysis, only the number of imaging planes (≥2 vs 1) was a significant factor affecting heterogeneity (p<0.01). Sensitivity analyses showed that specificity estimates were comparable and consistently high across all subgroups, but sensitivity estimates demonstrated some differences. Studies using two or more planes (n=4) had the highest sensitivity (0.99 [95% CI 0.98-1.00]).
CONCLUSIONS: Contemporary MRI shows excellent sensitivity and specificity for detection of bone metastasis in patients with prostate cancer. Using two or more imaging planes may further improve sensitivity. However, caution is needed in applying our results due to the heterogeneity among the included studies. PATIENT
SUMMARY: We reviewed studies using contemporary magnetic resonance imaging (MRI) for the detection of bone metastasis in prostate cancer patients. MRI shows excellent diagnostic performance in finding patients with bone metastasis.
Copyright © 2017 European Association of Urology. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Bone metastasis; Magnetic resonance imaging; Meta-analysis; Prostate cancer; Systematic review

Mesh:

Year:  2017        PMID: 28412063     DOI: 10.1016/j.eururo.2017.03.042

Source DB:  PubMed          Journal:  Eur Urol        ISSN: 0302-2838            Impact factor:   20.096


  15 in total

1.  68Ga-PSMA-PET/CT in comparison with 18F-fluoride-PET/CT and whole-body MRI for the detection of bone metastases in patients with prostate cancer: a prospective diagnostic accuracy study.

Authors:  Eva Dyrberg; Helle W Hendel; Tri Hien Viet Huynh; Tobias Wirenfeldt Klausen; Vibeke B Løgager; Claus Madsen; Erik M Pedersen; Maria Pedersen; Henrik S Thomsen
Journal:  Eur Radiol       Date:  2018-08-21       Impact factor: 5.315

2.  Comparison of PSMA-PET/CT, choline-PET/CT, NaF-PET/CT, MRI, and bone scintigraphy in the diagnosis of bone metastases in patients with prostate cancer: a systematic review and meta-analysis.

Authors:  Jing Zhou; Zhengxing Gou; Renhui Wu; Yuan Yuan; Guiquan Yu; Yigang Zhao
Journal:  Skeletal Radiol       Date:  2019-05-24       Impact factor: 2.199

Review 3.  The role of MRI in prostate cancer: current and future directions.

Authors:  Maria Clara Fernandes; Onur Yildirim; Sungmin Woo; Hebert Alberto Vargas; Hedvig Hricak
Journal:  MAGMA       Date:  2022-03-16       Impact factor: 2.533

4.  Diagnostic performance of 18F-choline PET-CT in prostate cancer.

Authors:  P Samper Ots; A Luis Cardo; C Vallejo Ocaña; M A Cabeza Rodríguez; L A Glaria Enríquez; M L Couselo Paniagua; J Olivera Vegas
Journal:  Clin Transl Oncol       Date:  2018-11-17       Impact factor: 3.405

Review 5.  Typical aspects in the rehabilitation of cancer patients suffering from metastatic bone disease or multiple myeloma.

Authors:  Mohammad Keilani; Franz Kainberger; Anna Pataraia; Timothy Hasenöhrl; Barbara Wagner; Stefano Palma; Fadime Cenik; Richard Crevenna
Journal:  Wien Klin Wochenschr       Date:  2019-07-02       Impact factor: 1.704

6.  Clinical association between pre-treatment levels of plasma fibrinogen and bone metastatic burden in newly diagnosed prostate cancer patients.

Authors:  Gan-Sheng Xie; Gang Li; Yu Li; Jin-Xian Pu; Yu-Hua Huang; Jin-Hu Li; Hu-Ming Yin
Journal:  Chin Med J (Engl)       Date:  2019-11-20       Impact factor: 2.628

7.  Diagnostic performance of magnetic resonance imaging for colorectal liver metastasis: A systematic review and meta-analysis.

Authors:  Yitao Mao; Bin Chen; Haofan Wang; Youming Zhang; Xiaoping Yi; Weihua Liao; Luqing Zhao
Journal:  Sci Rep       Date:  2020-02-06       Impact factor: 4.379

Review 8.  Salvage therapy for prostate cancer after radical prostatectomy.

Authors:  Nicholas G Zaorsky; Jeremie Calais; Stefano Fanti; Derya Tilki; Tanya Dorff; Daniel E Spratt; Amar U Kishan
Journal:  Nat Rev Urol       Date:  2021-08-06       Impact factor: 14.432

9.  Downregulation of miRNA-205 Expression and Biological Mechanism in Prostate Cancer Tumorigenesis and Bone Metastasis.

Authors:  Yu Sun; Sheng-Hua Li; Ji-Wen Cheng; Gang Chen; Zhi-Guang Huang; Yong-Yao Gu; Hai-Biao Yan; Mao-Lin He
Journal:  Biomed Res Int       Date:  2020-10-29       Impact factor: 3.411

10.  Whole-body magnetic resonance imaging (WB-MRI) reporting with the METastasis Reporting and Data System for Prostate Cancer (MET-RADS-P): inter-observer agreement between readers of different expertise levels.

Authors:  Paola Pricolo; Eleonora Ancona; Paul Summers; Jorge Abreu-Gomez; Sarah Alessi; Barbara Alicja Jereczek-Fossa; Ottavio De Cobelli; Franco Nolè; Giuseppe Renne; Massimo Bellomi; Anwar Roshanali Padhani; Giuseppe Petralia
Journal:  Cancer Imaging       Date:  2020-10-27       Impact factor: 3.909

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.